Loading…
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
Background. With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance is emerging. Methods. Patients with infection or colonization due to colistin-resistant A. baumannii were identified at a hospital system in...
Saved in:
Published in: | Clinical infectious diseases 2015-05, Vol.60 (9), p.1295-1303 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c524t-f5421cd4e44cae555ff8ca9c020970f51627a3fa26a56a1ffccb997e88b0a0373 |
---|---|
cites | cdi_FETCH-LOGICAL-c524t-f5421cd4e44cae555ff8ca9c020970f51627a3fa26a56a1ffccb997e88b0a0373 |
container_end_page | 1303 |
container_issue | 9 |
container_start_page | 1295 |
container_title | Clinical infectious diseases |
container_volume | 60 |
creator | Qureshi, Zubair A. Hittle, Lauren E. O'Hara, Jessica A. Rivera, Jesabel I. Syed, Alveena Shields, Ryan K. Pasculle, Anthony W. Ernst, Robert K. Doi, Yohei |
description | Background. With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance is emerging. Methods. Patients with infection or colonization due to colistin-resistant A. baumannii were identified at a hospital system in Pennsylvania. Clinical data were collected from electronic medical records. Susceptibility testing, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST) were performed. To investigate the mechanism of colistin resistance, lipid A was subjected to matrix-assisted laser desorption/ionization mass spectrometry. Results. Twenty patients with colistin-resistant A. baumannii were identified. Ventilator-associated pneumonia was the most common type of infection. Nineteen patients had received intravenous and/or inhaled CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection prior to identification of colistin-resistant isolates. The 30-day all-cause mortality rate was 30%. The treatment regimen for colistin-resistant A. baumannii infection associated with the lowest mortality rate was a combination of CMS, a carbapenem, and ampicillin-sulbactam. The colistin-susceptible and -resistant isolates from the same patients were highly related by PFGE, but isolates from different patients were not, suggesting evolution of resistance during CMS therapy. By MLST, all isolates belonged to the international clone II, the lineage that is epidemic worldwide. Phosphoethanolamine modification of lipid A was present in all colistin-resistant A. baumannii isolates. Conclusions. Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection. Lipid A modification by the addition of phosphoethanolamine accounted for colistin resistance. Susceptibility testing for colistin should be considered for A. baumannii identified from CMS-experienced patients. |
doi_str_mv | 10.1093/cid/civ048 |
format | article |
fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4462660</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>26365261</jstor_id><sourcerecordid>26365261</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-f5421cd4e44cae555ff8ca9c020970f51627a3fa26a56a1ffccb997e88b0a0373</originalsourceid><addsrcrecordid>eNptkd1rFDEUxUNR2lr74rsyIIIURm8-Z8aHQl1aWygIYp_DnWyiWWaSbTJT6H_fLNsvpQ8hF84v555wCHlH4QuFjn81flnODYh2h-xTyZtayY6-KjPIthYtb_fIm5xXAJS2IHfJHpOKM6CwT84XcfB58qH-ZXMZMEzVifHBTrFHM9lU9TiPGIL336rv9jaGZbXA1OPaBjtWD4-MfUteOxyyPby_D8jV2envxXl9-fPHxeLksjaSial2UjBqlsIKYdBKKZ1rDXYGGHQNOEkVa5A7ZAqlQuqcMX3XNbZte0DgDT8gx1vf9dyPdmlsmBIOep38iOlWR_T6XyX4v_pPvNFCKKYUFIPP9wYpXs82T3r02dhhwGDjnDVVDVNQYtCCfvwPXcU5hfK9DSUBRENZoY62lEkx52TdYxgKelOQLgXpbUEF_vA8_iP60EgB3m-BVZ5ietIVV5KpTaZPL-llFePQPHF31keimQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1675004712</pqid></control><display><type>article</type><title>Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford Journals Online</source><creator>Qureshi, Zubair A. ; Hittle, Lauren E. ; O'Hara, Jessica A. ; Rivera, Jesabel I. ; Syed, Alveena ; Shields, Ryan K. ; Pasculle, Anthony W. ; Ernst, Robert K. ; Doi, Yohei</creator><creatorcontrib>Qureshi, Zubair A. ; Hittle, Lauren E. ; O'Hara, Jessica A. ; Rivera, Jesabel I. ; Syed, Alveena ; Shields, Ryan K. ; Pasculle, Anthony W. ; Ernst, Robert K. ; Doi, Yohei</creatorcontrib><description>Background. With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance is emerging. Methods. Patients with infection or colonization due to colistin-resistant A. baumannii were identified at a hospital system in Pennsylvania. Clinical data were collected from electronic medical records. Susceptibility testing, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST) were performed. To investigate the mechanism of colistin resistance, lipid A was subjected to matrix-assisted laser desorption/ionization mass spectrometry. Results. Twenty patients with colistin-resistant A. baumannii were identified. Ventilator-associated pneumonia was the most common type of infection. Nineteen patients had received intravenous and/or inhaled CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection prior to identification of colistin-resistant isolates. The 30-day all-cause mortality rate was 30%. The treatment regimen for colistin-resistant A. baumannii infection associated with the lowest mortality rate was a combination of CMS, a carbapenem, and ampicillin-sulbactam. The colistin-susceptible and -resistant isolates from the same patients were highly related by PFGE, but isolates from different patients were not, suggesting evolution of resistance during CMS therapy. By MLST, all isolates belonged to the international clone II, the lineage that is epidemic worldwide. Phosphoethanolamine modification of lipid A was present in all colistin-resistant A. baumannii isolates. Conclusions. Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection. Lipid A modification by the addition of phosphoethanolamine accounted for colistin resistance. Susceptibility testing for colistin should be considered for A. baumannii identified from CMS-experienced patients.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/civ048</identifier><identifier>PMID: 25632010</identifier><language>eng</language><publisher>United States: Oxford University Press</publisher><subject>Acinetobacter baumannii - drug effects ; Acinetobacter baumannii - genetics ; Acinetobacter baumannii - isolation & purification ; Acinetobacter baumannii - pathogenicity ; Acinetobacter Infections - complications ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - microbiology ; Acinetobacter Infections - mortality ; Adult ; Aged ; Aged, 80 and over ; Ampicillin - therapeutic use ; and Commentaries ; ARTICLES AND COMMENTARIES ; Bacterial infections ; Carbapenems - pharmacology ; Carbapenems - therapeutic use ; Colistin - pharmacology ; Colistin - therapeutic use ; CRE bacteria ; Drug resistance ; Drug Resistance, Multiple, Bacterial ; Drug use ; Electronic Health Records ; Electrophoresis, Gel, Pulsed-Field ; Ethanolamines - chemistry ; Female ; Gram-negative bacteria ; Humans ; Lipid A - chemistry ; Lipids ; Male ; Mass spectrometry ; Microbial Sensitivity Tests ; Middle Aged ; Multilocus Sequence Typing ; Pneumonia, Ventilator-Associated - drug therapy ; Pneumonia, Ventilator-Associated - microbiology ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization ; Sulbactam - therapeutic use</subject><ispartof>Clinical infectious diseases, 2015-05, Vol.60 (9), p.1295-1303</ispartof><rights>Copyright © 2015 Oxford University Press on behalf of the Infectious Diseases Society of America</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</rights><rights>Copyright Oxford University Press, UK May 1, 2015</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: . 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-f5421cd4e44cae555ff8ca9c020970f51627a3fa26a56a1ffccb997e88b0a0373</citedby><cites>FETCH-LOGICAL-c524t-f5421cd4e44cae555ff8ca9c020970f51627a3fa26a56a1ffccb997e88b0a0373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/26365261$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/26365261$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25632010$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Qureshi, Zubair A.</creatorcontrib><creatorcontrib>Hittle, Lauren E.</creatorcontrib><creatorcontrib>O'Hara, Jessica A.</creatorcontrib><creatorcontrib>Rivera, Jesabel I.</creatorcontrib><creatorcontrib>Syed, Alveena</creatorcontrib><creatorcontrib>Shields, Ryan K.</creatorcontrib><creatorcontrib>Pasculle, Anthony W.</creatorcontrib><creatorcontrib>Ernst, Robert K.</creatorcontrib><creatorcontrib>Doi, Yohei</creatorcontrib><title>Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>Background. With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance is emerging. Methods. Patients with infection or colonization due to colistin-resistant A. baumannii were identified at a hospital system in Pennsylvania. Clinical data were collected from electronic medical records. Susceptibility testing, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST) were performed. To investigate the mechanism of colistin resistance, lipid A was subjected to matrix-assisted laser desorption/ionization mass spectrometry. Results. Twenty patients with colistin-resistant A. baumannii were identified. Ventilator-associated pneumonia was the most common type of infection. Nineteen patients had received intravenous and/or inhaled CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection prior to identification of colistin-resistant isolates. The 30-day all-cause mortality rate was 30%. The treatment regimen for colistin-resistant A. baumannii infection associated with the lowest mortality rate was a combination of CMS, a carbapenem, and ampicillin-sulbactam. The colistin-susceptible and -resistant isolates from the same patients were highly related by PFGE, but isolates from different patients were not, suggesting evolution of resistance during CMS therapy. By MLST, all isolates belonged to the international clone II, the lineage that is epidemic worldwide. Phosphoethanolamine modification of lipid A was present in all colistin-resistant A. baumannii isolates. Conclusions. Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection. Lipid A modification by the addition of phosphoethanolamine accounted for colistin resistance. Susceptibility testing for colistin should be considered for A. baumannii identified from CMS-experienced patients.</description><subject>Acinetobacter baumannii - drug effects</subject><subject>Acinetobacter baumannii - genetics</subject><subject>Acinetobacter baumannii - isolation & purification</subject><subject>Acinetobacter baumannii - pathogenicity</subject><subject>Acinetobacter Infections - complications</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Acinetobacter Infections - microbiology</subject><subject>Acinetobacter Infections - mortality</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Ampicillin - therapeutic use</subject><subject>and Commentaries</subject><subject>ARTICLES AND COMMENTARIES</subject><subject>Bacterial infections</subject><subject>Carbapenems - pharmacology</subject><subject>Carbapenems - therapeutic use</subject><subject>Colistin - pharmacology</subject><subject>Colistin - therapeutic use</subject><subject>CRE bacteria</subject><subject>Drug resistance</subject><subject>Drug Resistance, Multiple, Bacterial</subject><subject>Drug use</subject><subject>Electronic Health Records</subject><subject>Electrophoresis, Gel, Pulsed-Field</subject><subject>Ethanolamines - chemistry</subject><subject>Female</subject><subject>Gram-negative bacteria</subject><subject>Humans</subject><subject>Lipid A - chemistry</subject><subject>Lipids</subject><subject>Male</subject><subject>Mass spectrometry</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Multilocus Sequence Typing</subject><subject>Pneumonia, Ventilator-Associated - drug therapy</subject><subject>Pneumonia, Ventilator-Associated - microbiology</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><subject>Sulbactam - therapeutic use</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><recordid>eNptkd1rFDEUxUNR2lr74rsyIIIURm8-Z8aHQl1aWygIYp_DnWyiWWaSbTJT6H_fLNsvpQ8hF84v555wCHlH4QuFjn81flnODYh2h-xTyZtayY6-KjPIthYtb_fIm5xXAJS2IHfJHpOKM6CwT84XcfB58qH-ZXMZMEzVifHBTrFHM9lU9TiPGIL336rv9jaGZbXA1OPaBjtWD4-MfUteOxyyPby_D8jV2envxXl9-fPHxeLksjaSial2UjBqlsIKYdBKKZ1rDXYGGHQNOEkVa5A7ZAqlQuqcMX3XNbZte0DgDT8gx1vf9dyPdmlsmBIOep38iOlWR_T6XyX4v_pPvNFCKKYUFIPP9wYpXs82T3r02dhhwGDjnDVVDVNQYtCCfvwPXcU5hfK9DSUBRENZoY62lEkx52TdYxgKelOQLgXpbUEF_vA8_iP60EgB3m-BVZ5ietIVV5KpTaZPL-llFePQPHF31keimQ</recordid><startdate>20150501</startdate><enddate>20150501</enddate><creator>Qureshi, Zubair A.</creator><creator>Hittle, Lauren E.</creator><creator>O'Hara, Jessica A.</creator><creator>Rivera, Jesabel I.</creator><creator>Syed, Alveena</creator><creator>Shields, Ryan K.</creator><creator>Pasculle, Anthony W.</creator><creator>Ernst, Robert K.</creator><creator>Doi, Yohei</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150501</creationdate><title>Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance</title><author>Qureshi, Zubair A. ; Hittle, Lauren E. ; O'Hara, Jessica A. ; Rivera, Jesabel I. ; Syed, Alveena ; Shields, Ryan K. ; Pasculle, Anthony W. ; Ernst, Robert K. ; Doi, Yohei</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-f5421cd4e44cae555ff8ca9c020970f51627a3fa26a56a1ffccb997e88b0a0373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acinetobacter baumannii - drug effects</topic><topic>Acinetobacter baumannii - genetics</topic><topic>Acinetobacter baumannii - isolation & purification</topic><topic>Acinetobacter baumannii - pathogenicity</topic><topic>Acinetobacter Infections - complications</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Acinetobacter Infections - microbiology</topic><topic>Acinetobacter Infections - mortality</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Ampicillin - therapeutic use</topic><topic>and Commentaries</topic><topic>ARTICLES AND COMMENTARIES</topic><topic>Bacterial infections</topic><topic>Carbapenems - pharmacology</topic><topic>Carbapenems - therapeutic use</topic><topic>Colistin - pharmacology</topic><topic>Colistin - therapeutic use</topic><topic>CRE bacteria</topic><topic>Drug resistance</topic><topic>Drug Resistance, Multiple, Bacterial</topic><topic>Drug use</topic><topic>Electronic Health Records</topic><topic>Electrophoresis, Gel, Pulsed-Field</topic><topic>Ethanolamines - chemistry</topic><topic>Female</topic><topic>Gram-negative bacteria</topic><topic>Humans</topic><topic>Lipid A - chemistry</topic><topic>Lipids</topic><topic>Male</topic><topic>Mass spectrometry</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Multilocus Sequence Typing</topic><topic>Pneumonia, Ventilator-Associated - drug therapy</topic><topic>Pneumonia, Ventilator-Associated - microbiology</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</topic><topic>Sulbactam - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Qureshi, Zubair A.</creatorcontrib><creatorcontrib>Hittle, Lauren E.</creatorcontrib><creatorcontrib>O'Hara, Jessica A.</creatorcontrib><creatorcontrib>Rivera, Jesabel I.</creatorcontrib><creatorcontrib>Syed, Alveena</creatorcontrib><creatorcontrib>Shields, Ryan K.</creatorcontrib><creatorcontrib>Pasculle, Anthony W.</creatorcontrib><creatorcontrib>Ernst, Robert K.</creatorcontrib><creatorcontrib>Doi, Yohei</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Qureshi, Zubair A.</au><au>Hittle, Lauren E.</au><au>O'Hara, Jessica A.</au><au>Rivera, Jesabel I.</au><au>Syed, Alveena</au><au>Shields, Ryan K.</au><au>Pasculle, Anthony W.</au><au>Ernst, Robert K.</au><au>Doi, Yohei</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2015-05-01</date><risdate>2015</risdate><volume>60</volume><issue>9</issue><spage>1295</spage><epage>1303</epage><pages>1295-1303</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>Background. With an increase in the use of colistin methansulfonate (CMS) to treat carbapenem-resistant Acinetobacter baumannii infections, colistin resistance is emerging. Methods. Patients with infection or colonization due to colistin-resistant A. baumannii were identified at a hospital system in Pennsylvania. Clinical data were collected from electronic medical records. Susceptibility testing, pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST) were performed. To investigate the mechanism of colistin resistance, lipid A was subjected to matrix-assisted laser desorption/ionization mass spectrometry. Results. Twenty patients with colistin-resistant A. baumannii were identified. Ventilator-associated pneumonia was the most common type of infection. Nineteen patients had received intravenous and/or inhaled CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection prior to identification of colistin-resistant isolates. The 30-day all-cause mortality rate was 30%. The treatment regimen for colistin-resistant A. baumannii infection associated with the lowest mortality rate was a combination of CMS, a carbapenem, and ampicillin-sulbactam. The colistin-susceptible and -resistant isolates from the same patients were highly related by PFGE, but isolates from different patients were not, suggesting evolution of resistance during CMS therapy. By MLST, all isolates belonged to the international clone II, the lineage that is epidemic worldwide. Phosphoethanolamine modification of lipid A was present in all colistin-resistant A. baumannii isolates. Conclusions. Colistin-resistant A. baumannii occurred almost exclusively among patients who had received CMS for treatment of carbapenem-resistant, colistin-susceptible A. baumannii infection. Lipid A modification by the addition of phosphoethanolamine accounted for colistin resistance. Susceptibility testing for colistin should be considered for A. baumannii identified from CMS-experienced patients.</abstract><cop>United States</cop><pub>Oxford University Press</pub><pmid>25632010</pmid><doi>10.1093/cid/civ048</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1058-4838 |
ispartof | Clinical infectious diseases, 2015-05, Vol.60 (9), p.1295-1303 |
issn | 1058-4838 1537-6591 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4462660 |
source | JSTOR Archival Journals and Primary Sources Collection; Oxford Journals Online |
subjects | Acinetobacter baumannii - drug effects Acinetobacter baumannii - genetics Acinetobacter baumannii - isolation & purification Acinetobacter baumannii - pathogenicity Acinetobacter Infections - complications Acinetobacter Infections - drug therapy Acinetobacter Infections - microbiology Acinetobacter Infections - mortality Adult Aged Aged, 80 and over Ampicillin - therapeutic use and Commentaries ARTICLES AND COMMENTARIES Bacterial infections Carbapenems - pharmacology Carbapenems - therapeutic use Colistin - pharmacology Colistin - therapeutic use CRE bacteria Drug resistance Drug Resistance, Multiple, Bacterial Drug use Electronic Health Records Electrophoresis, Gel, Pulsed-Field Ethanolamines - chemistry Female Gram-negative bacteria Humans Lipid A - chemistry Lipids Male Mass spectrometry Microbial Sensitivity Tests Middle Aged Multilocus Sequence Typing Pneumonia, Ventilator-Associated - drug therapy Pneumonia, Ventilator-Associated - microbiology Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Sulbactam - therapeutic use |
title | Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A04%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Colistin-Resistant%20Acinetobacter%20baumannii:%20Beyond%20Carbapenem%20Resistance&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Qureshi,%20Zubair%20A.&rft.date=2015-05-01&rft.volume=60&rft.issue=9&rft.spage=1295&rft.epage=1303&rft.pages=1295-1303&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/civ048&rft_dat=%3Cjstor_pubme%3E26365261%3C/jstor_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c524t-f5421cd4e44cae555ff8ca9c020970f51627a3fa26a56a1ffccb997e88b0a0373%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1675004712&rft_id=info:pmid/25632010&rft_jstor_id=26365261&rfr_iscdi=true |